Đang chuẩn bị liên kết để tải về tài liệu:
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

The prognosis of patients with advanced biliary tract cancer (BTC) who have progressed on gemcit‑abine plus cisplatin is dismal. Trifluridine/tipiracil (FTD/TPI) and irinotecan have proven efficacy in different gastroin‑ testinal malignancies. We therefore hypothesized that this combination might improve the therapeutic outcome in patients with BTC after failure of first-line treatment. |

TÀI LIỆU LIÊN QUAN